PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
100.00%
Gross profit growth exceeding 1.5x TRVN's 27.07%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
10.75%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
-21.32%
G&A reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.47%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
1.47%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
6.88%
Similar D&A growth to TRVN's 6.74%. Walter Schloss would investigate industry patterns.
-1.39%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-1.47%
Operating income decline while TRVN shows 14.24% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-3.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.89%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.89%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
2.63%
EPS growth while TRVN declines. John Neff would investigate advantages.
2.63%
Diluted EPS growth while TRVN declines. John Neff would investigate advantages.
3.22%
Share count reduction below 50% of TRVN's 0.01%. Michael Burry would check for concerns.
3.22%
Diluted share reduction below 50% of TRVN's 0.01%. Michael Burry would check for concerns.